INT635

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1975
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 51
Total Number 51
Disease Relevance 24.50
Pain Relevance 12.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MAOB) small molecule metabolic process (MAOB) oxidoreductase activity (MAOB)
Anatomy Link Frequency
platelet 8
brain 5
basal ganglia 2
thalamus 2
heart 1
MAOB (Homo sapiens)
Pain Link Frequency Relevance Heat
sSRI 260 100.00 Very High Very High Very High
monoamine 177 100.00 Very High Very High Very High
Dopamine 391 99.78 Very High Very High Very High
aspirin 2 99.78 Very High Very High Very High
medulla 6 99.76 Very High Very High Very High
fluoxetine 80 99.66 Very High Very High Very High
sNRI 34 99.66 Very High Very High Very High
transdermal 12 99.60 Very High Very High Very High
antidepressant 223 99.38 Very High Very High Very High
Migraine 24 99.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
Brain Death 184 100.00 Very High Very High Very High
Disease 1627 99.60 Very High Very High Very High
Nicotine Addiction 122 99.58 Very High Very High Very High
Headache 59 99.32 Very High Very High Very High
Drug Induced Neurotoxicity 32 99.28 Very High Very High Very High
Cluster Headache 1 98.96 Very High Very High Very High
Depression 806 98.36 Very High Very High Very High
Parkinson's Disease 94 98.16 Very High Very High Very High
Migraine Disorders 14 97.76 Very High Very High Very High
Dementia 47 96.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Some other explanation other than MAO inhibition must be sought to explain how oral phentermine increases platelet 5-HT, since platelet MAO-B does not metabolize platelet 5-HT, and since amphetamine-type drugs are even weaker inhibitors of MAO-B than MAO-A.
Negative_regulation (inhibitors) of MAO-B in platelet
1) Confidence 0.59 Published 1999 Journal Synapse Section Abstract Doc Link 10231134 Disease Relevance 0.16 Pain Relevance 0.12
The introduction of reversible inhibitors of monoamine oxidase-A (RIMAs) has greatly reduced both the number and severity of these interactions and, in particular, the risk of hypertensive crises following the ingestion of tyramine (the "cheese effect").
Negative_regulation (inhibitors) of monoamine oxidase associated with pressure and volume under development and monoamine
2) Confidence 0.56 Published 1993 Journal Clin Neuropharmacol Section Abstract Doc Link 8313396 Disease Relevance 0.26 Pain Relevance 0.29
The mechanism for rasagiline’s neuroprotection may in part relate to MAO-B inhibition.
Negative_regulation (inhibition) of MAO-B
3) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 1.23 Pain Relevance 0.09
Platelet MAO-B inhibition correlates well with brain MAO-B, and serves as a marker of MAO-B activity.
Negative_regulation (inhibition) of MAO-B in Platelet
4) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.06 Pain Relevance 0.04
Inhibition of MAO-B by rasagiline is irreversible.
Negative_regulation (Inhibition) of MAO-B
5) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.07 Pain Relevance 0.04
Efficacy of selective MAO-B inhibition in treating early PD was initially established for selegiline (deprenyl) in DATATOP (Deprenyl and Tocopherol Antioxidative therapy of Parkinsonism).6,7 In this multicenter placebo-controlled study, 800 patients with early, untreated PD were randomized to receive deprenyl 10 mg/day, tocopherol (vitamin E) 2,000 IU/day, both, or placebo.
Negative_regulation (inhibition) of MAO-B associated with parkinson's disease and disease
6) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.42 Pain Relevance 0.34
It also has a role in deaminating betaphenylethylamine, which stimulates release of dopamine and inhibits its reuptake.5 Therefore, inhibition of MAO-B increases available dopamine.
Negative_regulation (inhibition) of MAO-B associated with dopamine
7) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.31 Pain Relevance 0.40
The mechanism cannot be solely accounted for by MAO-B inhibition.
Negative_regulation (inhibition) of MAO-B
8) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.71 Pain Relevance 0.08
This has revealed that 35% of MAO-B activity was inhibited within one hour of administration of 1 mg rasagiline in healthy volunteers.18,19 (11) C-I-deprenyl PET was able to detect decrease MAO-B activity in the thalamus and basal ganglia immediately after a 10-day period of administering rasagiline to healthy volunteers.
Negative_regulation (decrease) of MAO-B in basal ganglia associated with thalamus
9) Confidence 0.53 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2695242 Disease Relevance 0.05 Pain Relevance 0.05
Transitory decrease in platelet monoamine-oxidase activity during migraine attacks.
Negative_regulation (decrease) of monoamine-oxidase in platelet associated with aspirin, migraine and monoamine
10) Confidence 0.49 Published 1977 Journal Lancet Section Title Doc Link 65511 Disease Relevance 0.19 Pain Relevance 0.43
A highly significant decrease in platelet monoamine-oxidase activity has been observed in migrainous subjects during a migraine attack compared with activity outside an attack.
Negative_regulation (decrease) of monoamine-oxidase in platelet associated with migraine and monoamine
11) Confidence 0.49 Published 1977 Journal Lancet Section Abstract Doc Link 65511 Disease Relevance 0.17 Pain Relevance 0.35
As the first MAO-B inhibitor approved for the treatment of Parkinson's disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors.
Negative_regulation (inhibitor) of MAO-B associated with disease
12) Confidence 0.43 Published 1998 Journal Drug Saf Section Abstract Doc Link 9673855 Disease Relevance 0.64 Pain Relevance 0.10
Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease.
Negative_regulation (inhibitor) of MAO-B associated with disease and monoamine
13) Confidence 0.43 Published 1998 Journal Drug Saf Section Abstract Doc Link 9673855 Disease Relevance 0.50 Pain Relevance 0.05
Our results showed that the 5-hydroxytryptamine (5-HT) content in platelets was: (1) increased in the subgroup of anti-social alcoholics; (2) transiently and differently altered in alcoholics compared to opiate addicts; and (3) lowered in drinking alcoholics and normal in alcoholics who were drinking as well as smoking (that may occur via MAO-B inhibition by smoke).
Negative_regulation (inhibition) of MAO-B in platelets associated with nicotine addiction and opiate
14) Confidence 0.43 Published 1997 Journal Psychiatry Res Section Abstract Doc Link 9406907 Disease Relevance 0.42 Pain Relevance 0.34
Incubation of MDMA treated cells with the SERT inhibitor, fluoxetine (500 nM) or the MAO-B inhibitor, L-deprenyl (0.1 mM) for 30 min prior to DA, significantly blocked free radical production and cell death.
Negative_regulation (inhibitor) of MAO-B associated with dopamine, death and fluoxetine
15) Confidence 0.43 Published 2004 Journal Neurosci. Lett. Section Abstract Doc Link 15308297 Disease Relevance 0.26 Pain Relevance 0.54
Efforts should be made in understanding the relationship between specific biochemical markers and traits (such as monoamine oxidase deficiency and tyramine sensitivity); precipitants related to the migraine attack; and epidemiologic characteristics such as age at onset and sex.
Negative_regulation (deficiency) of monoamine oxidase associated with migraine and monoamine
16) Confidence 0.41 Published 1984 Journal Epidemiol Rev Section Abstract Doc Link 6092121 Disease Relevance 0.91 Pain Relevance 0.94
When selegiline is dosed at 10 mg a day or less in PD, it can serve as an irreversible inhibitor of brain MAO-B enzyme.
Negative_regulation (inhibitor) of MAO-B enzyme in brain associated with disease
17) Confidence 0.40 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515908 Disease Relevance 1.01 Pain Relevance 0.61
If used in high doses, MAO-B inhibitors will be active for A and B pathways.
Negative_regulation (inhibitors) of MAO-B
18) Confidence 0.40 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515908 Disease Relevance 1.11 Pain Relevance 0.65
Thus, selegiline, at its usual clinical dose, should not exert an antidepressant effect because it selectively inhibits MAO-B (and not MAO-A) enzymes in the adult human brain.
Negative_regulation (inhibits) of MAO-B in brain associated with antidepressant
19) Confidence 0.40 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515908 Disease Relevance 0.97 Pain Relevance 0.54
It is presently contraindicated to use the antimigraine drug sumatriptan with selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, or lithium.
Negative_regulation (inhibitors) of monoamine oxidase associated with cluster headache, sumatriptan, ssri and monoamine
20) Confidence 0.40 Published 1995 Journal J Clin Psychopharmacol Section Abstract Doc Link 7782482 Disease Relevance 0.24 Pain Relevance 0.85

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox